CL2009000557A1 - Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos - Google Patents
Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menosInfo
- Publication number
- CL2009000557A1 CL2009000557A1 CL2009000557A CL2009000557A CL2009000557A1 CL 2009000557 A1 CL2009000557 A1 CL 2009000557A1 CL 2009000557 A CL2009000557 A CL 2009000557A CL 2009000557 A CL2009000557 A CL 2009000557A CL 2009000557 A1 CL2009000557 A1 CL 2009000557A1
- Authority
- CL
- Chile
- Prior art keywords
- active principle
- solid preparation
- methylacrylate
- fine granules
- methacrylic acid
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- 239000011247 coating layer Substances 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title abstract 2
- 229920001577 copolymer Polymers 0.000 title abstract 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 title 1
- 229960003174 lansoprazole Drugs 0.000 title 1
- NZEXUPLJXSDMCK-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O.COC(=O)C(C)=C NZEXUPLJXSDMCK-UHFFFAOYSA-N 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 239000010410 layer Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008061673 | 2008-03-11 | ||
| JP2008334920 | 2008-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009000557A1 true CL2009000557A1 (es) | 2010-10-01 |
Family
ID=40791576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009000557A CL2009000557A1 (es) | 2008-03-11 | 2009-03-10 | Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9241910B2 (https=) |
| EP (1) | EP2254556A2 (https=) |
| JP (1) | JP5604304B2 (https=) |
| KR (1) | KR20100129761A (https=) |
| CN (2) | CN104127368A (https=) |
| AR (1) | AR070863A1 (https=) |
| AU (1) | AU2009224254A1 (https=) |
| BR (1) | BRPI0909439A2 (https=) |
| CA (1) | CA2717947C (https=) |
| CL (1) | CL2009000557A1 (https=) |
| CO (1) | CO6321224A2 (https=) |
| CR (1) | CR11709A (https=) |
| DO (1) | DOP2010000273A (https=) |
| EA (1) | EA021792B1 (https=) |
| EC (1) | ECSP10010538A (https=) |
| GE (1) | GEP20135845B (https=) |
| IL (1) | IL207989A0 (https=) |
| MA (1) | MA32174B1 (https=) |
| MX (1) | MX2010009824A (https=) |
| MY (1) | MY173730A (https=) |
| NZ (1) | NZ588407A (https=) |
| PE (2) | PE20091620A1 (https=) |
| TW (1) | TWI441658B (https=) |
| UY (1) | UY31698A (https=) |
| WO (1) | WO2009113703A2 (https=) |
| ZA (1) | ZA201006679B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| CN102119027A (zh) * | 2008-06-26 | 2011-07-06 | 麦克内尔-Ppc股份有限公司 | 含有药物活性剂的包衣颗粒 |
| KR101565621B1 (ko) | 2009-01-26 | 2015-11-03 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 저치환도 히드록시프로필셀룰로오스 수분산액을 이용한 습식 조립 타정법 |
| EP2319504A1 (en) * | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
| US20130216617A1 (en) * | 2010-06-29 | 2013-08-22 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| MX2013007588A (es) * | 2010-12-27 | 2013-08-09 | Takeda Pharmaceutical | Comprimido de desintegracion oral. |
| CN102716097A (zh) * | 2012-05-29 | 2012-10-10 | 浙江华海药业股份有限公司 | 控制口腔崩解片药物释放速率的方法 |
| FI126168B (en) * | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3257511B1 (en) * | 2015-02-10 | 2018-10-24 | FUJIFILM Corporation | Orally disintegrating tablet and method for manufacturing same |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| JP6905972B2 (ja) * | 2016-02-23 | 2021-07-21 | ニプロ株式会社 | 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法 |
| WO2017147318A1 (en) | 2016-02-23 | 2017-08-31 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens |
| GB201607548D0 (en) * | 2016-04-29 | 2016-06-15 | Univ Central Lancashire | Solid dosage form |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| CN110121342A (zh) * | 2016-12-28 | 2019-08-13 | 富士胶片富山化学株式会社 | 医药组合物 |
| KR102555664B1 (ko) * | 2017-02-21 | 2023-07-18 | 이에이 파마 가부시키가이샤 | 과립 제제 |
| JP7235193B2 (ja) * | 2017-04-26 | 2023-03-08 | 大正製薬株式会社 | 固形組成物 |
| JP7009288B2 (ja) * | 2017-05-18 | 2022-01-25 | エルメッド株式会社 | 湿製錠剤の製造方法及び湿製錠剤の品質向上方法 |
| JP7336187B2 (ja) * | 2017-11-30 | 2023-08-31 | 日本ケミファ株式会社 | 多層構造を有する粒子状医薬組成物 |
| CN111712235A (zh) | 2018-01-16 | 2020-09-25 | 应用材料公司 | 金属氧化物包封的药物组合物及其制备方法 |
| JP7108041B2 (ja) | 2018-01-24 | 2022-07-27 | パーデュー、ファーマ、リミテッド、パートナーシップ | 睡眠障害の治療及び予防 |
| WO2019156904A1 (en) * | 2018-02-08 | 2019-08-15 | Taiwanj Pharmaceuticals Co., Ltd. | Pharmaceutical formulation for a solid dosage form of opioid receptor antagonists |
| CN113301957A (zh) | 2019-01-31 | 2021-08-24 | 普渡制药公司 | 取代的喹喔啉型桥接哌啶化合物的多晶型形式 |
| EP4021421A4 (en) | 2019-08-27 | 2023-05-10 | Applied Materials, Inc. | VAPOR PHASE COATINGS FOR PHARMACEUTICAL SOLUTION CONTROL |
| EP4021423A4 (en) | 2019-08-27 | 2023-11-08 | Applied Materials, Inc. | Vapor phase coating technology for pharmaceutical abuse deterrent formulations |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
| EP4096791A1 (en) | 2020-01-31 | 2022-12-07 | Nanocopoeia LLC | Amorphous nilotinib microparticles and uses thereof |
| WO2021222739A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| TWI870622B (zh) | 2020-10-02 | 2025-01-21 | 美商應用材料股份有限公司 | 製備氧化矽塗佈藥品的低溫處理 |
| CN112121067A (zh) * | 2020-11-16 | 2020-12-25 | 深圳科兴药业有限公司 | 一种婴儿型双歧杆菌微胶囊及其制备方法 |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CA3216359A1 (en) | 2021-04-07 | 2022-10-13 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| MX2023013514A (es) | 2021-05-21 | 2024-04-02 | Purdue Pharma Lp | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. |
| WO2023056304A1 (en) | 2021-09-30 | 2023-04-06 | Applied Materials, Inc. | Low temperature silicon oxide coating for pharmaceutical applications |
| JPWO2023182332A1 (https=) * | 2022-03-22 | 2023-09-28 | ||
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025085818A1 (en) | 2023-10-19 | 2025-04-24 | Purdue Pharma L.P. | Sunobinop for use in method of treating alcohol use disorder |
| CN117180213A (zh) * | 2023-10-23 | 2023-12-08 | 湖南洞庭药业股份有限公司 | 奥沙西泮片组合物及其制备和稳定化方法 |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| CN117860699A (zh) * | 2024-01-07 | 2024-04-12 | 长沙晶易医药科技股份有限公司 | 一种细粒剂及其制备方法 |
| KR20260019740A (ko) * | 2024-08-02 | 2026-02-10 | 일양약품주식회사 | 일라프라졸, 제산제 및 알칼리화제를 포함하는 안정한 약제학적 조성물 및 이의 제조방법 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| DE69934505T2 (de) | 1998-05-18 | 2007-10-04 | Takeda Pharmaceutical Co. Ltd. | Im munde zerfallende tablette enthaltend ein benzimidazole |
| TW585786B (en) | 1998-07-28 | 2004-05-01 | Takeda Chemical Industries Ltd | Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition |
| EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| US6897205B2 (en) | 2001-01-31 | 2005-05-24 | Roehm Gmbh & Co. Kg | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| AU2002316020B2 (en) | 2001-07-16 | 2007-03-15 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| DE10208335A1 (de) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
| AUPS167602A0 (en) | 2002-04-12 | 2002-05-16 | F.H. Faulding & Co. Limited | An improved modified release preparation |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| US20040096497A1 (en) | 2002-11-19 | 2004-05-20 | Ponder Garratt W. | Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions |
| MXPA04010956A (es) | 2003-01-30 | 2005-01-25 | Roehm Gmbh | Forma de dosis farmaceutica y metodo para la produccion de la misma. |
| KR20060065632A (ko) | 2003-07-17 | 2006-06-14 | 닥터 레디스 래보러토리즈, 인코포레이티드 | 팽창성 코팅을 갖는 약제학적 조성물 |
| NZ546183A (en) | 2003-09-26 | 2011-04-29 | Alza Corp | Controlled release formulations exhibiting an ascending rate of release |
| GB0323232D0 (en) * | 2003-10-03 | 2003-11-05 | Rolls Royce Plc | Electrical machine |
| WO2005079752A2 (en) | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| US20050181052A1 (en) | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
| CA2558535A1 (en) | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical composition comprising an acid labile drug |
| EP1721604A4 (en) | 2004-03-04 | 2008-04-30 | Takeda Pharmaceutical | STABLE CAPSULE PREPARATION |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| RU2382637C2 (ru) * | 2004-04-30 | 2010-02-27 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию |
| DE102004035936A1 (de) | 2004-07-23 | 2006-03-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
| WO2006101536A1 (en) * | 2004-11-04 | 2006-09-28 | Akina, Inc. | Fast-melting tablets having taste-masking and sustained release properties |
| WO2006070845A1 (ja) | 2004-12-28 | 2006-07-06 | Eisai R & D Management Co., Ltd. | 速崩壊性錠剤及びその製造方法 |
| GB0502479D0 (en) | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| FR2885526B1 (fr) | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
| DE102005024614A1 (de) | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| EP1901719A2 (en) | 2005-07-11 | 2008-03-26 | Nycomed Danmark ApS | Benzimidazole formulation |
| DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| US20090148519A1 (en) | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP1813275A1 (en) * | 2005-12-20 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
| US20070141151A1 (en) | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| JP2009519334A (ja) * | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| EP1962844A2 (en) | 2005-12-20 | 2008-09-03 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
| US8486450B2 (en) | 2005-12-28 | 2013-07-16 | Takeda Pharmaceutical Company Limited | Method of producing solid preparation disintegrating in the oral cavity |
| KR100762847B1 (ko) | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
| EP1837016A3 (en) | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| US20090068263A1 (en) | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
| HUE029173T2 (hu) | 2006-04-26 | 2017-02-28 | Alphapharm Pty Ltd | Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot |
| EP2614818A1 (en) | 2006-04-28 | 2013-07-17 | Wockhardt Limited | Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor |
| AU2007261098A1 (en) | 2006-06-19 | 2007-12-27 | Mcneil-Ppc, Inc. | Enteric coated particles containing an active ingredient |
| US20090291136A1 (en) | 2006-07-11 | 2009-11-26 | Lek Pharmaceuticals D.D. | Multiple Unit Tablets |
| EP2068837A2 (en) | 2006-07-28 | 2009-06-17 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
| CA2662123C (en) | 2006-08-30 | 2015-12-01 | Jagotec Ag | Controlled release oral dosage formulations comprising a core and one or more barrier layers |
| EP2098250B1 (en) | 2006-12-28 | 2016-09-28 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| DK2152250T3 (da) | 2007-05-07 | 2019-12-09 | Evonik Degussa Gmbh | Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse |
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| US20100015239A1 (en) | 2008-07-17 | 2010-01-21 | Ahmed Salah U | Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
| MX2013007588A (es) | 2010-12-27 | 2013-08-09 | Takeda Pharmaceutical | Comprimido de desintegracion oral. |
-
2009
- 2009-03-10 TW TW098107630A patent/TWI441658B/zh not_active IP Right Cessation
- 2009-03-10 UY UY0001031698A patent/UY31698A/es not_active Application Discontinuation
- 2009-03-10 AU AU2009224254A patent/AU2009224254A1/en not_active Abandoned
- 2009-03-10 AR ARP090100842A patent/AR070863A1/es unknown
- 2009-03-10 GE GEAP2009011969 patent/GEP20135845B/en unknown
- 2009-03-10 US US12/921,731 patent/US9241910B2/en active Active
- 2009-03-10 CN CN201410370293.2A patent/CN104127368A/zh active Pending
- 2009-03-10 BR BRPI0909439A patent/BRPI0909439A2/pt not_active Application Discontinuation
- 2009-03-10 WO PCT/JP2009/054983 patent/WO2009113703A2/en not_active Ceased
- 2009-03-10 MY MYPI2010004253A patent/MY173730A/en unknown
- 2009-03-10 PE PE2009000349A patent/PE20091620A1/es not_active Application Discontinuation
- 2009-03-10 KR KR1020107022551A patent/KR20100129761A/ko not_active Ceased
- 2009-03-10 PE PE2014000364A patent/PE20141034A1/es not_active Application Discontinuation
- 2009-03-10 NZ NZ588407A patent/NZ588407A/en not_active IP Right Cessation
- 2009-03-10 JP JP2010536259A patent/JP5604304B2/ja not_active Expired - Fee Related
- 2009-03-10 EA EA201071054A patent/EA021792B1/ru not_active IP Right Cessation
- 2009-03-10 EP EP09720410A patent/EP2254556A2/en not_active Withdrawn
- 2009-03-10 CA CA2717947A patent/CA2717947C/en active Active
- 2009-03-10 MX MX2010009824A patent/MX2010009824A/es not_active Application Discontinuation
- 2009-03-10 CN CN200980116971.XA patent/CN102026627B/zh not_active Expired - Fee Related
- 2009-03-10 CL CL2009000557A patent/CL2009000557A1/es unknown
-
2010
- 2010-09-05 IL IL207989A patent/IL207989A0/en unknown
- 2010-09-10 DO DO2010000273A patent/DOP2010000273A/es unknown
- 2010-09-17 ZA ZA2010/06679A patent/ZA201006679B/en unknown
- 2010-09-29 MA MA33210A patent/MA32174B1/fr unknown
- 2010-09-30 CR CR11709A patent/CR11709A/es unknown
- 2010-10-11 EC EC2010010538A patent/ECSP10010538A/es unknown
- 2010-10-11 CO CO10125889A patent/CO6321224A2/es not_active Application Discontinuation
-
2014
- 2014-10-21 US US14/519,979 patent/US20150037423A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000557A1 (es) | Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos | |
| CO6551722A2 (es) | Composiciones y tabletas farmacéuticas con recubrimiento o compresible y métodos de fabricación | |
| AR069905A1 (es) | Formulacion de liberacion controlada, preventiva de mal uso, en donde el agente farmaceuticamente activo es un farmaco con capacidad de abuso | |
| CL2013001586A1 (es) | Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion. | |
| MX2008012731A (es) | Tabletas de paracetamol de liberacion rapida. | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| WO2008146178A3 (en) | A novel tablet dosage form | |
| NO20091501L (no) | Farmasoytiske sammensetninger | |
| CO6300931A2 (es) | Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos | |
| WO2011084593A3 (en) | Abuse-resistant formulations | |
| WO2011110939A3 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
| WO2013158814A8 (en) | Immediate release, abuse deterrent pharmaceutical compositions | |
| WO2009043926A3 (en) | Oral fast disintegrating tablets | |
| WO2010015567A3 (en) | Controlled release formulations using intelligent polymers | |
| WO2011106416A3 (en) | Abuse-resistant formulations | |
| WO2007143155A3 (en) | Sustained release pharmaceutical dosage form containing phenylephrine | |
| CL2013003161A1 (es) | Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion. | |
| WO2008052033A3 (en) | Ibuprofen composition | |
| ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
| WO2010127205A3 (en) | Fixed dose drug combination formulations | |
| WO2011101863A3 (en) | Extended release pharmaceutical compositions of lacosamide | |
| EP2234598C0 (fr) | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives | |
| WO2011140446A3 (en) | Pharmaceutical formulations | |
| WO2009149058A3 (en) | Modified release niacin formulations | |
| WO2012052834A3 (en) | Multiple unit particulate system comprising metoprolol succinate |